Neutralising monoclonal antibodies (nMABs) or antivirals for non-hospitalised patients with COVID-19

A COVID-19 therapeutic alert has been issued: neutralising monoclonal antibodies (nMABs) or antivirals for non-hospitalised patients with COVID-19.

From the 16 December, access to monoclonal antibodies as a treatment for COVID-19 will be extended to non-hospitalised patients who are PCR positive and aged 12 and above who are considered at highest risk of progression to severe disease, hospital admission or death. 

Eligible patients may receive antiviral therapy if an nMAB is contraindicated. The published interim clinical commissioning policy will be reviewed, if required, as further data emerge on the population prevalence of the omicron variant and any impact on the efficacy of COVID therapies.

Further information and actions can be found in the COVID-19 therapeutic alert and interim clinical commissioning policy: neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19.